REXULTI® (Brexpiprazole) FDA Approved for Treating Agitation in Alzheimer's Disease Patients

REXULTI® (brexpiprazole) has been approved by the FDA for treating agitation associated with dementia due to Alzheimer's disease, making it the first and only pharmacological treatment for this indication in the US.

Important News for Older Adults: FDA Approves First Drug to Treat

FDA Approves Rexulti for Agitation Associated With Dementia Due to

For Alzheimer's Agitation, Promising News from Rexulti

Decision on Brexpiprazole for Alzheimer's Agitation Due in May

Otsuka and Lundbeck Issue Statement on REXULTI for Alzheimer's

FDA Approves First Drug for Alzheimer's-Related Agitation Symptoms

FDA Approves Brexpiprazole for Agitation Associated with Alzheimer

A silent struggle: Caregiving for a patient with agitation

REXULTI® (Brexpiprazole) FDA Approved for Treating Agitation in

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

A first: FDA approves drug to treat agitation in Alzheimer's

Controversy Surrounds Brexpiprazole's FDA Approval, a New

FDA Approves First Drug to Treat Dementia-Associated Agitation in

First-Ever Drug for Alzheimer's Agitation, Brexpiprazole, Nears